Loading...
Loading...
Browse all stories on DeepNewz
VisitJudo Bio Launches with $100M to Develop RNA Kidney Drugs Using STRIKE Platform
Oct 7, 2024, 12:16 PM
Judo Bio has debuted with a $100 million launch, aiming to develop RNA drugs targeting the kidney. The company plans to utilize its Selectively Targeting RNA Into KidnEy (STRIKE) platform to develop ligand-siRNA conjugates. The launch comes less than two months after Borealis Bio's $150 million launch for similar RNA kidney drugs. Judo Bio's leadership includes CEO Rajiv Patni and CSO Alfica Sehgal, with backing from Atlas Venture and TCG. The company is taking a page from Alnylam's playbook and is part of the broader startups ecosystem.
View original story
Markets
Yes • 50%
No • 50%
Clinical trial results published by Judo Bio or in clinical trial registries
No • 50%
Yes • 50%
Official announcements from Judo Bio or the partnering company
No • 50%
Yes • 50%
Official press releases from Judo Bio or financial news outlets
3 drugs • 25%
1 drug • 25%
4 or more drugs • 25%
2 drugs • 25%
Company announcements or drug pipeline updates
Phase 3 initiation • 25%
Phase 2 completion • 25%
Preclinical success • 25%
Phase 1 completion • 25%
Company announcements or clinical trial registry updates
2028 or later • 25%
Before 2026 • 25%
2026 • 25%
2027 • 25%
FDA approval announcements or company press releases